Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Canrenoate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 5/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.81 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.81 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | AR | P10275 | 4/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Canrenoate SCHEMBL18775372 | 1.00 | PGR (0.81) | PGRTDP1NR3C1LMNAPDE4D | |
| Canrenoate SCHEMBL11341384 | 1.00 | PGR (0.81) | PGRTDP1NR3C1LMNAPDE4D | |
| Canrenoate SCHEMBL3510075 | 1.00 | PGR (0.81) | PGRTDP1NR3C1LMNAPDE4D | |
| Canrenoate SCHEMBL7424152 | 0.91 | TDP1 (0.68) | PGRTDP1NR3C1LMNAPDE4D | |
| Canrenoate SCHEMBL49729 | 0.90 | PGR (1.00) | PGRTDP1NR3C1LMNAPDE4D | |
| Canrenoate SCHEMBL124160 | 0.90 | PGR (1.00) | PGRTDP1NR3C1LMNAPDE4D | |
| SCHEMBL7797159 | 0.87 | PGR (0.71) | PGRTDP1NR3C1LMNAPDE4D | |
| SCHEMBL11647042 | 0.86 | PGR (0.73) | PGRTDP1NR3C1LMNAPDE4D | |
| SCHEMBL10890105 | 0.86 | PGR (0.73) | PGRTDP1NR3C1LMNAPDE4D | |
| SCHEMBL11799754 | 0.86 | PGR (0.61) | PGRTDP1NR3C1LMNAPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 686 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-20250206779-A1 | ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | UNIVERSIDAD DE CHILE (CL) | 2025-06-26 | — | — | US | claimed |
| WO-2025050228-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE OR A COMBINATION OF PEPTIDES AGONISTIC TO THE MAS, AT1 AND AT2 RECEPTORS | PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) | 2025-03-13 | — | — | WO | claimed |
| US-12145951-B2 | Inorganic-organic hybrid compounds including organic platinum-containing anions, for use in medicine | KARLSRUHER INSTITUT FUR TECHNOLOGIE (DE) | 2024-11-19 | — | — | US | claimed |
| US-20240341301-A1 | ITACONATE AND DERIVATIVES THEREOF FOR THE PROTECTION OF CELLS, TISSUES, AND ORGANS | UNIV MICHIGAN REGENTS (US) | 2024-10-17 | — | — | US | claimed |
| US-20240173337-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) | 2024-05-30 | — | — | US | claimed |
| EP-4356142-A1 | BIOMARKER AND DRUG COMBINATIONS FOR HEART FAILURE PREDICTION | Endothelium Scanning Nanotechnology Limited (AU) | 2024-04-24 | — | — | EP | claimed |
| EP-4337675-A1 | ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Universidad De Chile (CL) | 2024-03-20 | — | — | EP | claimed |
| EP-4313153-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117062626-A | Methods and compositions for treating sleep apnea | 爱普宁公司(特拉华) | 2023-11-14 | — | — | CN | claimed |
| EP-0253226-B1 | AQUEOUS ALCALINE INJECTABLE SOLUTION OF TORASEMID READY FOR USE AND PROCESS FOR PREPARATION THEREOF | Roche Diagnostics GmbH (DE) | 1990-06-06 | — | — | EP | claimed |
| US-4861786-A | Composition for a stable vein compatible injectable solution of torasemide process for the preparation and method of use | BOEHRINGER MANNHEIM GMBH (DE) | 1989-08-29 | — | — | US | claimed |
| US-4684635-A | SEBACEOUS GLAND HYPERTROPHY, HIRSUTISM | Orentreich, Norman (US) | 1987-08-04 | — | — | US | claimed |
| EP-0030681-B1 | DIRECTLY INJECTABLE AQUEOUS SOLUTIONS OF THE ALKALI SALTS OF CANRENOIC ACID AND OF FUROSEMIDE, AND PROCESS FOR THEIR PRODUCTION | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-06-13 | — | — | EP | claimed |
| US-4323500-A | REACTING WITH A THIOCARBOXYLIC ACID | MITSUBISHI CHEMICAL INDUSTRIES, LIMITED (JP) | 1982-04-06 | — | — | US | claimed |
| US-4301160-A | Ready for use, injectable, aqueous solutions of alkali metal salts of canrenoic acid and furosemide and process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-11-17 | — | — | US | claimed |
| US-4267106-A | New process for the preparation 17β-hydroxy-3-oxo-17α-pregnene and pregnadiene-21-carboxylic acid γ-lactones | GIST BROCADES N.V. (NL) | 1981-05-12 | — | — | US | claimed |
| US-4213902-A | Process for producing steroidal 7α-acylthio-4-en-3-ones | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) | 1980-07-22 | — | — | US | claimed |
| US-4155906-A | Process for preparing steroidal 3-oxo-4,6-dienes such as 17-hydroxy-3-oxo-17α-pregna-4,6-diene-21-carboxylic acidγ-lactone | G. D. SEARLE & CO. (US) | 1979-05-22 | — | — | US | claimed |
| US-4088759-A | Injectable pharmaceutical solutions | BOEHRINGER MANNHEIM GMBH (DT) | 1978-05-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240341301-A1 | ITACONATE AND DERIVATIVES THEREOF FOR THE PROTECTION OF CELLS, TISSUES, AND ORGANS | TNNI3, ALDH2, ALDH5A1 | PGR 4719/4885TDP1 292/4885NR3C1 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.